| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2142364 | Lung Cancer | 2010 | 6 Pages |
Abstract
Amrubicin is an active and well-tolerated regimen in patients with previously treated lung cancer. Amrubicin 35Â mg/m2 seems to achieve similar efficacy with less toxicity than amrubicin 40Â mg/m2 in this patient population. These results warrant further evaluation in previously treated lung cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kyoichi Kaira, Noriaki Sunaga, Yoshio Tomizawa, Noriko Yanagitani, Kimihiro Shimizu, Hisao Imai, Mitsuyoshi Utsugi, Yasuki Iwasaki, Hironobu Iijima, Hiroaki Tsurumaki, Akihiro Yoshii, Naoto Fueki, Takeshi Hisada, Tamotsu Ishizuka, Ryusei Saito,